Traditional CAR-T technology
Traditional CAR-T technology has made remarkable achievements in hematological tumors, with products already approved and on the market. However, traditional CAR-T technology has not shown significant efficacy in solid tumors.
ICT’s next generation CAR-T technology for solid tumors
The next generation of CAR-T technology, CoupledCARTM, developed by ICT, focuses on solving the main problems encountered in the treatment of solid tumors. CoupledCARTM optimizes target selection and greatly enhances the efficacy of the CAR-T therapy. IRB-approved human trials in thyroid cancer and colorectal cancer show that the effect of ICT’s CoupledCARTM technology is remarkable.